ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Case Report

Case Report: Efficacy of propranolol in delaying the growth of hemangioblastomas in a Von Hippel Lindau patient

[version 1; peer review: 2 approved with reservations]
PUBLISHED 13 Mar 2017
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the Rare diseases collection.

Abstract

Von Hippel Lindau is an inherited disease which leads to tumor growth, including hemangioblastomas in the central nervous system and retina. No pharmacological treatment has demonstrated efficacy. Propranolol is a beta-blocker widely used in some neurological and cardiac diseases, and its safety is known. We present a patient diagnosed with Von Hippel Lindau disease who was treated with propranolol for worsening migraine. The patient exhibited two asymptomatic hemangioblastomas, which showed no change in size during treatment with propranolol. Our case report suggests that propranolol could be effective in delaying the growth of hemangioblastomas in the central nervous system.

Keywords

Propranolol, hemangioblastomas, Von Hippel Lindau disease, case report

Case description

A 33-year-old Caucasian female who was diagnosed with Von Hippel Lindau (VHL) disease in 2002. Her mother suffered sudden death in 2002; and a diagnosis of VHL was made at her autopsy. Therefore, the patient was studied by a neurologist, and one hemangioblastoma (HB) of 2cm in size was observed at the medulla during magnetic resonance imaging (MRI). The patient exhibited no symptoms; however, she underwent surgery in 2003 for the risk of complications due to the size of the HB. The patient’s recovery was uneventful. Since then an annual MRI of the central nervous system (CNS) has been performed.

From 2009, a progressive tumor growth of two HBs in the medulla was observed, which was checked annually by the neurosurgeon because the patient was asymptomatic.

Furthermore, the patient suffered from occasional migraine episodes since 2003. She presented with a worsening of her previous migraine, having headache attacks everyday since October 2013. After discussing the various treatment options, the patient opted for propranolol at increasing doses up to 120 mg per day starting in March of 2014. At the 3 month follow-up visit after starting propranolol, the patient reported a slight reduction in her migraines; however the dose was increased to 160 mg per day because patient still suffered more than 10 migraine episodes per month. No adverse events were observed during that period of time. At the 9 month follow-up visit, 6 months after 160mg per day of intake, she showed a significant improvement. During propranolol treatment, the patient underwent a cerebral and spinal cord MRI in October 2014, which showed no changes from the previous scan performed one year before. The patient continued to take propranolol; however, side effects appeared (orthostatic hypotension) in March 2015 (after 12 months of propranolol treatment) and necessitated a slow decrease in propranolol dosage until the treatment was stopped in July 2015. Subsequently, the patient’s migraine did not worsen; however, a clear growth in the medullary HBs was shown by control MRI (Figure 1) in October 2015. The patient required surgery in January 2016, due to an increase in tumor size observed in MRI. Since then the patient has remained asymptomatic.

3d18538e-8a73-4659-b273-82c2e81ccb63_figure1.gif

Figure 1. Hemangioblastoma and cyst during propranolol treatment (left) and after propranolol withdrawal (right).

Discussion

VHL disease, a rare autosomal dominant disorder, is caused by the deletion or mutation of the VHL tumor suppressor gene13. It has been reported that the absence of functional VHL protein, which occurs in the disease, often leads to the formation of highly vascular tumors, such as hemangioblastomas (HBs)46. Although some antiangiogenic therapies have been tried7,8, there are currently no effective pharmacological therapies for HBs, thus surgery remains the standard procedure9. Our patient was monitored by means of an annual MRI to check the growth of the tumors. The images were reviewed by the neurosurgeon in order to determine if the hemangioblastomas were of sufficient size for safe surgery.

Propranolol is a beta-blocker that is offered as first line treatment in the prophylaxis of migraine10. It is also used for the treatment of essential tremor11, hypertension and some cardiac diseases. In our case, the patient suffered worsening of her migraine and propranolol administration was indicated. Propranolol has also a proven efficacy in infantile hemangioma treatment12. Furthermore, propranolol has shown an antiangiogenic effect13, and a recent publication indicates that propranolol reduces the viability of HBs cultivated in vitro14. In the light of these data and after discussing the options with the patient, she decided to continue taking propranolol; however due to symptomatic orthostatic hypotension, the patient had to stop. Unfortunately, the HBs showed clear growth in MRI after stopping treatment.

In summary, propranolol treatment appeared to inhibit growth of the HBs after several years of steady progression, as seen in the MRI results. Tumor growth commenced again once the treatment with propranolol was interrupted. Our case study suggests that propranolol can delay the growth of hemangioblastomas in the CNS.

Consent

Written informed consent for publication of the clinical details and images was obtained from the patient.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 13 Mar 2017
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Perona-Moratalla AB, Serrano-Heras G and Segura T. Case Report: Efficacy of propranolol in delaying the growth of hemangioblastomas in a Von Hippel Lindau patient [version 1; peer review: 2 approved with reservations]. F1000Research 2017, 6:256 (https://doi.org/10.12688/f1000research.9036.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 13 Mar 2017
Views
14
Cite
Reviewer Report 11 May 2017
Eric Jonasch, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 
Approved with Reservations
VIEWS 14
The authors describe a patient with VHL disease who demonstrated arrested growth of a CNS hemangioblastoma while being treated with propranolol and propose a causal relationship between propranolol therapy and hemangioblastoma growth arrest.  

The authors should ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Jonasch E. Reviewer Report For: Case Report: Efficacy of propranolol in delaying the growth of hemangioblastomas in a Von Hippel Lindau patient [version 1; peer review: 2 approved with reservations]. F1000Research 2017, 6:256 (https://doi.org/10.5256/f1000research.9724.r22531)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
15
Cite
Reviewer Report 25 Apr 2017
Marie Louise Mølgaard Binderup, Department of Cellular and Molecular Medicine, University of Copenhagen (UCPH), Copenhagen, Denmark 
Lone Sunde, Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark 
Approved with Reservations
VIEWS 15
Perona-Moratalla et al. describe an interesting case of a von Hippel-Lindau (vHL) patient treated with the beta-blocker Propanolol for migraines, where they have documented the progression of the patient’s CNS tumors, hemangioblastomas (HBs). The concurrent lack of tumor growth in ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Binderup MLM and Sunde L. Reviewer Report For: Case Report: Efficacy of propranolol in delaying the growth of hemangioblastomas in a Von Hippel Lindau patient [version 1; peer review: 2 approved with reservations]. F1000Research 2017, 6:256 (https://doi.org/10.5256/f1000research.9724.r22185)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 13 Mar 2017
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.